NCT01096667 - Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042) | Biotech Hunter

Enrollment

194

Participants

Timeline

Start Date

May 17, 2010

Primary Completion Date

February 9, 2011

Study Completion Date

February 25, 2011

Conditions

Diabetes Mellitus, Type 2Hypertension

Interventions

DRUG

Placebo to Ertuglilflozin 1 or 5 mg

Placebo to ertuglilflozin tablet 1 or 5 mg once daily for 28 days

DRUG

Ertugliflozin 1 mg

Ertugliflozin tablet 1 mg once daily for 28 days

DRUG

Ertugliflozin 5 mg

Ertugliflozin tablet 5 mg once daily for 28 days

DRUG

Ertugliflozin 25 mg

Ertugliflozin tablet 25 mg once daily for 28 days

DRUG

HCTZ 12.5mg

Hydrocholorthiazide (HCTZ) 12.5 mg capsule once daily for 28 days

DRUG

Placebo to HCTZ

Placebo to HCTZ 12.5 mg capsule once daily for 28 days

DRUG

Placebo to ertuglilflozin 25 mg

Placebo to ertuglilflozin tablet 25 mg once daily for 28 days